Skip to contentB
Biolargo, Inc.
B
BLGOBiolargo, Inc. Q2 2022 · 10-Q
Revenue$1.32M$1.32M+185.1% vs Q2 2021 Net Income-$1.33M-$1.33MN/M vs Q2 2021 EPS, diluted—
Gross Profit$623,000+210.0% Operating Income-$1,321,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biolargo, Inc. · CIK 880242 · Engraved from SEC EDGAR
Operating Cash Flowderived-$724,000N/M Margins · derivedGross margin47.1%+3.8 pt vs Q2 2021
Operating margin-99.8%+267.0 pt vs Q2 2021
Net margin-100.8%+285.0 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 15, 2022 · 46 d after period end